Press release
United States Ebola Vaccine Market Insights | Key Players, Regulatory Updates & Market Scope
Ebola Vaccine Market
According to DataM Intelligence has released its latest research report on "Ebola Virus Vaccine Market Size 2025," offering in-depth insights into key growth factors such as regional performance, market segmentation, CAGR trends, revenue analysis of leading players, and major drivers shaping the industry. This report provides a clear and forward-looking perspective on market size (both value and volume), emerging opportunities, and current development status helping businesses identify growth potential and make informed strategic decisions
According to WHO data from August 2023, two monoclonal antibody treatments mAb114 (Ansuvimab; Ebanga) and REGN-EB3 (Inmazeb) are strongly recommended for Ebola due to their proven effectiveness. Ebola's fatality rate averages around 50%, though it has varied between 25% and 90% in past outbreaks depending on conditions and response efforts.
Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/ebola-virus-vaccine-market?kb
In July 2024, the Sabin Vaccine Institute began a Phase 2 clinical trial in Uganda for its single-dose Sudan ebolavirus vaccine, which currently has no approved alternatives. The trial is being conducted with healthy volunteers at the Makerere University Walter Reed Project (MUWRP).
Zaire ebolavirus, the deadliest of the five Ebola virus species, is responsible for most global outbreaks. It causes hemorrhagic fever in humans and non-human primates, with fatality rates often exceeding 50%. First detected during the 1976 Ebola outbreak in Zaire, the virus was named after the region.
North America is home to major pharmaceutical companies and research institutions, including Merck & Co., Johnson & Johnson, and Moderna, which are at the forefront of Ebola vaccine development. They have introduced vaccines like Ervebo (V920) and continue to work on new formulations targeting multiple Ebola strains and combination vaccines.
In May 2024, RedHill Biopharma secured a new Chinese patent for opaganib as a treatment to inhibit single-stranded RNA virus replication, including Ebola. This patent, valid until 2035, enhances the company's intellectual property portfolio.
In August 2023, the U.S. FDA expanded the approval of Merck's ERVEBO vaccine to include children as young as 12 months, allowing its use for preventing Zaire ebolavirus in individuals aged 12 months and older. Previously, it was limited to those 18 and above.
Top Key Players:
Johnson & Johnson, Merck & Co., Inc., GSK plc., CansinoBl0, and AIM ImmunoTech Inc. among others.
Growth Projection:
The Global Ebola Virus Vaccine Market is set to witness significant growth between 2025 and 2032. While 2024 reflects steady progress, the increasing adoption of innovative strategies by leading players is expected to accelerate growth across the projected horizon. This creates a strong landscape of opportunities for businesses looking to expand, invest, and stay competitive in a rapidly evolving market.
Research Process:
The Ebola Virus Vaccine Market research report by DataM Intelligence leverages both primary and secondary data sources to deliver deep insights. It explores a wide range of factors shaping the industry from government regulations, market conditions, and competitive dynamics to historical trends, technological advancements, upcoming innovations, and potential challenges. This comprehensive analysis highlights growth prospects while addressing barriers, helping businesses navigate volatility and seize new opportunities
Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=ebola-virus-vaccine-market
Market Segmentation:
By Strain Type: Zaire Ebolavirus | Sudan Virus | Taï Forest Virus | Others
By Vaccine Type: rVSV-ZEBOV | Ad26.ZEBOV and MVA-BN-Filo | Others
By End-User: Hospitals | Specialized Clinics | Others
Top Growth Regions:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Benefits of the Report:
Chapter 1: Introduces the report with an overview of coverage summarizing key market segments by region, product type, and application. It offers a clear snapshot of market size, segment-wise growth potential, and both short- and long-term industry outlook.
Chapter 2: Brings forward the most valuable market insights and reveals the game-changing emerging trends shaping the industry's future.
Chapter 3: Provides a detailed analysis of the competitive landscape among Ebola Virus Vaccine covering revenue shares, strategic initiatives, and the latest mergers & acquisitions.
Chapter 4: Delivers comprehensive profiles of top players, including revenue, profit margins, product lines, and company milestones.
Chapters 5 & 6: Break down revenue performance across regions and countries, offering a precise view of market sizes, opportunities, and development prospects worldwide.
Chapter 7: Examines segmentation by type, revealing the size and potential of each category guiding businesses toward untapped, high-impact areas.
Chapter 8: Focuses on applications, evaluating how different downstream markets are growing and identifying promising sectors for expansion.
Chapter 9: Maps the entire industry supply chain, detailing both upstream and downstream activities for a holistic understanding.
Chapter 10: Concludes with key findings and the most critical takeaways giving stakeholders a clear direction for future strategies.
Get Customization in the report as per your requirements: https://datamintelligence.com/customize/ebola-virus-vaccine-market?kb
Q1: How fast is the Ebola Virus Vaccine Market growing?
A: The Market is on a robust growth path, expected to expand at a CAGR of 6.4% between 2025 and 2032.
Q2: Which Regions dominate the Ebola Virus Vaccine Market?
A: North America is projected to hold a major share of the global Ebola virus vaccine market.
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States Ebola Vaccine Market Insights | Key Players, Regulatory Updates & Market Scope here
News-ID: 4189660 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Pyrogen Testing Market Report 2025 - 2031: In-Depth Insights & Key Players | Mer …
The Global Pyrogen Testing Market was about US$1.3 billion in 2023. It is expected to grow to around US$ 2.87 billion by 2031, with a compound annual growth rate of about 11.95% during the forecast period from 2024 to 2031.
Pyrogen testing is crucial in the pharmaceutical and biotechnology industries. It ensures the safety of injectable drugs, vaccines, and medical devices by detecting fever-causing contaminants. The market is expanding due to…
Exosome Therapeutics Pipeline Insights Industry Intelligence: Clinical Trials, A …
DataM Intelligence has published a new research report on ""Exosome Therapeutics Pipeline Insights Market Size 2025"". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Free Sample PDF Of…
Fertigation & Chemigation Market in the US: Rapid Adoption of Smart Irrigation S …
The Global Fertigation and Chemigation Market is valued at approximately US$ 45.69 billion in 2024 and is projected to reach US$ 63.82 billion by 2029, growing at a CAGR of 7.2% during the forecast period. Market growth is fueled by the increasing need to maximize crop yields with limited resources, particularly in regions facing water scarcity. The adoption of precision agriculture technologies and advanced irrigation systems is further enhancing the…
United States Fish Oil for Aquafeed Market Analysis 2025 - 2031: Growth Drivers, …
Global Fish Oil for Aquafeed Market reached US$ 2.56 billion in 2022 and is expected to hit US$ 3.53 billion by 2031, growing at a rate of 4.1% from 2024 to 2031, according to DataM Intelligence.
The market growth comes from rising aquaculture production that aims to satisfy the growing global demand for seafood. Fish oil, which is high in omega-3 fatty acids EPA and DHA, is vital for enhancing fish…
More Releases for Ebola
Ebola Vaccine Market : Recent Discoveries and Innovations
The "Ebola Vaccine Market" forecast 2031 report analyses the present and future competitive scenario of the analytics industry. Ebola Vaccine Market report offers an in-depth analysis on segments including top companies, products, applications, revenue and regions. a number of topics including likewise market share, drivers, trends and methods. This report additionally offers insights into the latest growth and trends. It encapsulates key aspects of the market, with focus on leading…
Ebola Vaccine Market Deep Research 2025-2032 | Ebola vaccine market are Merck an …
Latest Qualitative Research Report on the Ebola Vaccine Market Size 2025, published by Coherent Market Insights, provides valuable insights into both regional and global markets projected to grow in value from 2025 to 2032. The comprehensive research explores into the evolving Market's dynamics, value chain analysis, prominent investment areas, competitive landscape, drivers and constraints, regional outlook, and key market segments. It's also provides the industry overview with growth analysis and…
Ebola Virus Vaccine Market 2022 | Detailed Report
The Ebola Virus Vaccine research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement. The competitive landscape is studied here in terms of product range, strategies, and prospects of the market's key players. Furthermore, the report offers insightful market data and information about the Ebola…
Ebola Vaccine Market Opportunity Analysis, 2018-2026
Ebola virus disease (EVD) causes viral hemorrhagic fever. It is a life threatening disease, which is spread to humans from animals. Direct contact with body fluids of infected person is one of largest causes of spread of this infection. Symptoms of Ebola disease include high fever, vomiting, sore throat, diarrhea, headache and muscular pain, and in few cases, internal or external bleeding. Although, there is no cure for Ebola virus…
Ebola Treatment Market to Develop Rapidly by 2024
Ebola viral infection was first observed in The Democratic Republic of Congo (named after a river called Zaire) in 1976. Ebola is a viral disease which frequently causes lethal haemorrhagic fever in humans. The harmful consequences of Ebola viral infection are that the viruses can be used as potential biological weapon. The symptoms of Ebola viral infection include sudden onset of fever, sore throat, headaches, extreme tiredness, vomiting, skin rash,…
Ebola Virus Vaccine Market & Pipeline Insight
Ebola virus infection, which was previously called Ebola hemorrhagic fever was discovered in 1976. The infection caused due to ebola virus originates from four different strains of ebola virus. These viruses generally are known to affect non-human primates, and are transmitted from wild animals to the humans and among the latter, it is known to spread through human-to-human transmission. The natural hosts of ebola virus are Fruit bats, which…
